Global Severe Hypoglycemia Treatment Market: Market Outlook
Severe hypoglycemia is well-defined as lowering of blood glucose levels. It is termed as a condition in which the glucose level in the blood decreases below the normal level. It is a severe complication that occurs in patients with diabetes mellitus. Hypoglycemia often makes an individual feel weak. The symptoms of hypoglycemia include nausea, headache, hunger and even fatal. The long-term complications associated to hypoglycemia included myocardial infarction, precipitation of acute cerebrovascular disease, retinal cell death, neurocognitive dysfunction, and loss of vision. The severity of hypoglycemia may differ from person to person, and it can develop in children as well as adults, especially those with diabetes. Thus, the global need to examine the clinical spectrum and control the burden of hypoglycemia to neglect the life-threatening complications has explored opportunities for the manufacturers to develop effective treatment solutions and penetrate the market.
According to National Institute of Health, in 2019 the prevalence of diabetes was estimated to be around 463 million. The prevalence rate was higher in the urban areas by 10.8% than rural which was estimated to be around 7.2%. In the high-income nations the prevalence rate of diabetes was estimated to be around 10.4% than low-income countries 4.0% which was expected to grow rapidly in the coming years.
Find Out More about the Report Coverage
What is the Repercussion of the Covid-19 Pandemic on the Growth of the Severe Hypoglycemia Treatment Market?
The COVID-19 pandemic represented a huge burden to public health as well as healthcare services worldwide. The healthcare services had faced severe challenges during COVID-19 pandemic outbreaks, resulting in major falloffs in the care provided to people with chronic diseases, including diabetes. Many outpatient clinics had to change their routine interactions with the patient and adopted telemedicine to monitor patients at home. Diabetologists were concerned about the glucose control that could be affected during the country-wide lockdown. The country-wide lockdown caused severe psychological stress carried out by social distancing, limited access to food supply, limited the possibility to exercise, and delays in hospital visits to avoid exposure to coronavirus infection especially in socio-economically weaker people in emerging countries. According to the National Institutes of Health (NIH) study, the COVID-19 lockdown projected to influence the risk of hypoglycemia in patients with T2DM, especially those receiving medications (sulphonylurea and metformin), insulin, hydroxychloroquine (HCQ) especially in patients with associated co-morbidities.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
What are the Key Trends Impacting Growth of the Severe Hypoglycemia Treatment Market?
The Severe Hypoglycemia Treatment Market is emerging in presence of several big manufacturers in the field of pharmaceutical and life sciences. Approaching the reimbursement policies has positively attracted and explored the market opportunities for the manufacturers. The growing investment in research and development area to develop effective products has boosted the severe hypoglycemia treatment market. Moreover, the market is more focused on the development and expand their opportunities by developing generic copies of complex drugs. For instance, Amphastar Pharmaceuticals developed the generic copy of glucagon with focusing on the ideal requirement based on safety, efficacy and low-cost product to meet the customers demand and improve the competition in the severe hypoglycemia treatment market. Collaborations, mergers and acquisitions among the emerging key players in the growing trend aiming to expand their product portfolio and penetrate the competitive severe hypoglycemia treatment market.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
What are the driving factors that expected to boost the Severe Hypoglycemia Treatment Market growth?
The rising incidence of severe hypoglycemia due to abnormal glucose level, lack of physical exercise, growing obesity in the growing population expects to drive the severe hypoglycemia treatment market during the forecast period. Increasing patient pool, growing awareness about early diagnosis, adoption of regular assessment are the driving factors expects to propel the severe hypoglycemia treatment market in the coming years. Rapid advancements in the healthcare sector, ad manufacturer approach towards novel formulation development to treat iatrogenic hypoglycemia expected the severe hypoglycemia treatment market to boost in the coming future. Besides, high investment by manufacturers, increasing clinical trials increasing pipeline therapy and regulatory approvals, expects to drive the severe hypoglycemia treatment market.
Explore Persistence Market Research’s expertise in promulgation of the business !
What are the restraining factors that can hamper the Severe Hypoglycemia Treatment Market growth?
Restriction of sampling methods in clinical trials, lack of awareness, high-cost impact during the study of the clinical trials. Rising adverse effects due to the consumption of complex formulation that can cause kidney disorder or other renal disorders are some of the restraining factors that are expected to hamper the growth of the severe hypoglycemia treatment market.
Key Segments of Severe Hypoglycemia Treatment Market Covered in the report
Based on product type, the Severe Hypoglycemia Treatment Market has been segmented as
Based on the route of administration, the Severe Hypoglycemia Treatment Market has been segmented as
Based on the mode of action, the Severe Hypoglycemia Treatment Market has been segmented as
- Glucose receptor angonist
- glucagon-like peptide-1 (GLP-1) receptor antagonist
- Somatostatin Receptor Subtype 2 (SSTR2) antagonist
- Insulin receptor is encoded by a single gene (INSR) antagonist
- Dipeptidyl peptidase-4 (DPP-4)
- sodium-glucose co-transporter 2 inhibitors (SGLT-2)
Based on the age group, the Severe Hypoglycemia Treatment Market has been segmented as
Based on the distribution channel, the Severe Hypoglycemia Treatment Market has been segmented as
- Hospital Pharmacies
- Online Pharmacies
- Independent Pharmacies
Based on the region, the Severe Hypoglycemia Treatment Market has been segmented as
- North America
- Latin America
- South Asia
- East Asia
- Middle East & Africa
Why the oral route segment accounted for the highest share in the Severe Hypoglycemia Treatment Market?
According to the research studies, the oral administration is more preferable as compared to other routes of administration. The oral route results in higher blood glucose concentration as compared to buccal and the sublingual route. In sublingual route providing sugar under the tongue resulted rise in the blood glucose that has increased shift towards oral route of administration.
How did the regulatory approvals expect to influence the Severe Hypoglycemia Treatment Market?
The regulatory approval for the effective novel treatment as well as for the devices is the main hurdle every manufacturer has to face to bring their product to the market. Undergoing several investigating tests and determinations, that meet the regulatory guidelines approves the product in the market. The emerging key players continue to focus on the research and development sector to design and develop novel solutions for the customers need.
For instance, in December 2020, the U.S. Food and Drug Administration (FDA) approved the first generic product of glucagon for injection USP, 1 mg/vial packaged in an emergency kit, for the treatment of severe hypoglycemia developed by Amphastar Pharmaceuticals. This approval reflects the FDA’s continued commitment to advancing patient access to the safe, effective, low-cost and high-quality generic drug product. Additionally, in June 2019, the FDA approved the first Baqsimi nasal glucagon powder for the emergency treatment of severe hypoglycemia developed by Eli Lilly.
Why hospital pharmacies segment accounted for the highest share in the Severe Hypoglycemia Treatment Market?
The hospital pharmacies segment dominated the severe hypoglycemia treatment market. Owing to the increasing patient pool, availability of stock and dispense inpatient as well as outpatient medication witnessed to account highest share.
Key players such as Eli Lilly and Company
- Xeris Pharmaceuticals Inc.
- Zealand Pharma
- Torrent Labs
- Taj Pharmaceuticals
- Novo Nordisk
- Amphastar Pharmaceuticals
- Fresenius Kabi
are actively involved in the severe hypoglycemia treatment market.
What strategies are the Key Players adopting to increase their market share in the Severe Hypoglycemia Treatment Market?
The emerging key players are extending opportunities in developing countries by highly investing in research areas to innovate to develop effective and low-cost treatment solutions that expect to enhance their revenue gains and shape their position in the competitive severe hypoglycemia treatment market.
The emerging key players are actively participating in collaborative agreements and acquisitions to increase their severe hypoglycemia treatment market penetration. Additionally, the companies are actively entering into strategic distribution agreements to expand their sales footprint worldwide.
What are the Key Opportunities in the Severe Hypoglycemia Treatment Market?
The several emerging as well as leading players are focusing on developing novel solutions to capture the unmet needs of the customers. Increasing pipeline therapies and solutions to develop low cost-effective treatment therapies and products has made the manufacture to explore new opportunities in the severe hypoglycemia treatment market. Concurrently, investments for increasing the production of severe hypoglycemia treatment products are expecting to project market growth in the coming years.
Why North America is dominating the Sales of the Severe Hypoglycemia Treatment Market?
North America witnessed to dominate global severe hypoglycemia treatment market, increasing prevalence of diabetes, well-established health care infrastructure and presence of leading manufacturers. The growing demand for automated technology in the region has gained popularity and witnessed to dominate the severe hypoglycemia treatment market. The high consumption of tobacco, alcohol and smoke has increased the prevalence rate of diabetes in the region. According to American Diabetes Association, in 2020, around 1.5 million patients were diagnosed with diabetes in America.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, product types, routes of administration, age groups, and distribution channels.
The report on the Severe Hypoglycemia Treatment Market covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Historical Actual Market Size, 2015 – 2019
- Market Size & Forecast 2020 to 2030
- Supply & Demand Value Chain
- Market Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
- Market Drivers and Restraints
Regional analysis for the Severe Hypoglycemia Treatment Market includes:
- North America
- Latin America
- East Asia
- South Asia
- Middle East & Africa
Report on Severe Hypoglycemia Treatment Market highlights:
- Shifting industry dynamics
- In-depth market segmentation
- Historical, current, and projected industry size
- Recent industry trends
- Key competition landscape
- Strategies of key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.